Significance of primary hyperparathyroidism in the management of osteoporosis

Otolaryngologic Clinics of North America

Volumn 37, Issue 4, 2004, Pages 751-761

  Saleem, Tipu Faiz M ^a,b,d   Horwith, Melvin ^b,c   Stack Jr , Brendan C ^b,c  

^a READING HOSPITAL AND MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d Reading PA 19601 ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CANCER GROWTH FACTOR; ESTROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN;

BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; BREAST CANCER; CANCELLOUS BONE; CARDIOVASCULAR DISEASE; CATABOLISM; CORTICAL BONE; DISEASE PREDISPOSITION; ESTROGEN DEFICIENCY; EVOLUTION; FRACTURE; GEOMETRY; HUMAN; HYPERCALCEMIA; MORBIDITY; MORTALITY; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT INDICATION; VITAMIN D DEFICIENCY;

BONE AND BONES; BONE DENSITY; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; HYPERPARATHYROIDISM; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PARATHYROIDECTOMY; RISK FACTORS;

EID: 3242676099     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2004.02.007     Document Type: Review

References (66)

1. Wermers R.A., Khosla S., Atkinson E.J., Hodgson S.F., O'Fallon W.M., Melton L.J. III. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 126:(6):1997;433-440
2. Bilezikian J.P. Primary hyperparathyroidism. When to observe and when to operate. Endocrinol Metab Clin N Am. 29:(3):2000;465-478
3. Silverberg S.J., Bilezikian J.P. Primary hyperparathyroidism: still evolving? J Bone Miner Res. 12:(5):1997;856-862
4. Miller P.D., Bilezikian J.P. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N98-N102
5. Khosla S., Melton J. III. Fracture risk in primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N103-N107
6. Bilezikian J.P., Silverberg S.J. Parathyroid hormone. Does it have a role in the pathogenesis of osteoporosis? Clin Lab Med. 20:(3):2000;559-567
7. Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 14:(6):1993;690-709
8. Canalis E. Skeletal growth factors. Marcus R., Feldmean D., Kelsey J. Osteoporosis. 1996;266-268 Academic Press, San Diego
9. Johansson A.G., Rosen C.L. The insulin like growth factors: potential anabolic agents for the skeleton. Whitfield J.E., Morley P. Anabolic treatment for osteoporosis. 1998;185-205 CRC Press, Boca Raton (FL)
10. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M., Martin T. Modulation of osteoclast differentiation and function by new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:(3):1999;345-357
11. Kanzawa M., Sugimoto T., Kanatani M., Chihara K. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol. 142:(6):2000;661-664
12. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 139:(11):1998;4743-4746
13. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 95:(7):1998;3597-3602
14. Duong L.T., Rodan G.A. The role of integrins in osteoclast function. J Bone Miner Metab. 17:(1):1999;1-6
15. Greenfield E.M., Gornik S.A., Horowitz M.C., Donahue H.J., Shaw S.M. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 8:(10):1993;1163-1171
16. Grey A., Mitnick M.A., Masiukiewicz U., Sun B.H., Rudikoff S., Jilka R.L., et al. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology. 140:(10):1999;4683-4690
17. Girasole G., Passeri G., Jilka R.L., Manolagas S.C. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 93:(4):1994;1516-1524
18. Eriksen E.F. Primary hyperparathyroidism: lessons from bone histomorphometry. J Bone Miner Res. 17:(Suppl 2):2002;N95-N97
19. Parfitt A.M., Rao D.S., Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res. 6:(Suppl 2):1991;S97-S101. [discussion S121-4]
20. Christiansen P., Steiniche T., Brockstedt H., Mosekilde L., Hessov I., Melsen F. Primary hyperparathyroidism: iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone. 14:(5):1993;755-762
21. Dempster D.W., Parisien M., Silverberg S.J., Liang X.G., Schnitzer M., Shen V., et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 84:(5):1999;1562-1566
22. Parisien M., Silverberg S.J., Shane E., de la Cruz L., Lindsay R., Bilezikian J.P. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab. 70:(4):1990;930-938
23. Vogel M., Hahn M., Delling G. Trabecular bone structure in patients with primary hyperparathyroidism. Virchows Arch. 426:(2):1995;127-134
24. Silverberg S.J., Locker F.G., Bilezikian J.P. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 81:(11):1996;4007-4012
25. Bilezikian J.P. Bone strength in primary hyperparathyroidism. Osteoporos Int. 14:(Suppl 5):2003;113-117
26. Rao D.S., Wilson R.J., Kleerekoper M., Parfitt A.M. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab. 67:(6):1988;1294-1298
27. Bilezikian J.P. Bone strength in primary hyperparathyroidism. Osteoporos Int. 14:(Suppl 5):2003;13-17
28. Melton L.J. III, Atkinson E.J., O'Fallon W.M., Heath H. III. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med. 152:(11):1992;2269-2273
29. Silverberg S.J., Bilezikian J.P. Incipient primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab. 88:(11):2003;5348-5352
30. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 140:(9):1999;4367- 4370
31. Insogna K., Mitnick M., Pascarella J., Nakchbandi I., Grey A., Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. J Bone Miner Res. 17:(Suppl 2):2002;N108-N116
32. Gallagher J.C., Wilkinson R. The effect of ethinyloestradiol on calcium and phosphorus metabolism of post-menopausal women with primary hyperparathyroidism. Clin Sci Mol Med. 45:(6):1973;785-802
33. Silverberg S.J., Shane E., Jacobs T.P., Siris E., Bilezikian J.P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 341:(17):1999;1249-1255
34. Khosla S., Melton J. III. Fracture risk in primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N103-N107
35. Khosla S., Melton L.J. III, Wermers R.A., Crowson C.S., O'Fallon W., Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 14:(10):1999;1700-1707
36. Lumb G.A., Stanbury S.W. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med. 56:(6):1974;833-839
37. A Silverberg S.J., Shane E., Dempster D.W., Bilezikian J.P. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 107:(6):1999;561-567
38. Miller P.D., Bilezikian J.P. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N98-N102
39. Christiansen P., Steiniche T., Brixen K., Hessov I., Melsen F., Heickendorff L., et al. Primary hyperparathyroidism: whole-body bone mineral density in surgically treated Danish patients: a three-year follow-up study. Bone. 25:(5):1999;597-602
40. Bilezikian J.P., Potts J.T. Jr., Fuleihan Gel-H., Kleerekoper M., Neer R., Peacock M., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 87:(12):2002;5353-5361
41. Boyanov M. Diagnostic discrepancies between two closely related forearm bone density measurement sites. J Clin Densitom. 4:(1):2001;63-71
42. Silverberg S.J., Gartenberg F., Jacobs T.P., Shane E., Siris E., Staron R.B., et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 80:(3):1995;729-734
43. Abugassa S., Nordenstrom J., Eriksson S., Mollerstrom G., Alveryd A. Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. Surgery. 107:(2):1990;128-133
44. Bilezikian J.P., Kulak C.A., Bandeira C., Voss D., Sobieszczyk S.M., Silverberg S.J., et al. Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab. 83:(3):1998;732-735
45. Parfitt A.M. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res. 17:(10):2002;1741-1743
46. Adami S., Braga V., Squaranti R., Rossini M., Gatti D., Zamberlan N. Bone measurements in asymptomatic primary hyperparathyroidism. Bone. 22:(5):1998;565-570
47. Seeman E. Clinical review 137: sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab. 86:(10):2001;4576-4584
48. Vestergaard P., Mollerup C.L., Frokjaer V.G., Christiansen P., Blichert-Toft M., Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 321:(7261):2000;598-602
49. Silverberg S.J., Shane E., de la Cruz L., Dempster D.W., Feldman F., Seldin D., et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 4:(3):1989;283-291
50. Parisien M., Mellish R.W., Silverberg S.J., Shane E., Lindsay R., Bilezikian J.P., et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res. 7:(8):1992;913-919
51. Rockoff S.D., Sweet E., Bleustein J. The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae. Calcif Tissue Res. 3:(2):1969;163-175
52. Faulkner K.G., Cann C.E., Hasegawa B.H. Effect of bone distribution on vertebral strength: assessment with patient-specific nonlinear finite element analysis. Radiology. 179:(3):1991;669-674
53. Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N146-N149
54. Grey A.B., Stapleton J.P., Evans M.C., Tatnell M.A., Reid I.R. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med. 125:(5):1996;360-368
55. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288:(3):2002;321-333
56. Zanchetta J.R., Bogado C.E. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res. 16:(1):2001;189-190
57. Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D., Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11:(6):1996;835-842
58. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., et al. MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 287:(7):2002;847-857
59. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 281:(23):1999;2189-2197
60. Rodan G.A. Bisphosphonates and primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N150-N153
61. Strewler G.J. Medical approaches to primary hyperparathyroidism. Endocrinol Metab Clin North Am. 29:(3):2000;523-539
62. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 88:(12):2003;5644-5649
63. Antoniucci D.M., Shoback D. Calcimimetics in the treatment of primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N141-N145
64. Heaney R.P. The basis for the post-parathyroidectomy increase in bone mass. J Bone Miner Res. 17:(Suppl 2):2002;N154-N157
65. National Institute of Health. Proceedings of the NIH Consensus Development Conference on diagnosis and management of asymptomatic primary hyperparathyroidism. Bethesda, Maryland, October 29-31, 1990. J Bone Miner Res. 6:(Suppl 2):1991;S1-S166
66. National Institute of Health. NIH Conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference statement. Ann Intern Med. 114:(7):1991;593-597